While it’s too early to say whether 2020’s record year of fund-raising constitutes a “new normal,” there’s consensus among buysiders and bankers that a cheap money environment will continue in 2021 as...

Targeted cancer programs are catching the eyes of buysiders as they kick off the New Year with a positive outlook for the capital markets. On the latest BioCentury This Week podcast, BioCentury editors discuss investor...

IO Biotech parlayed early clinical data into a €127 million ($154.8 million) series B financing led by HBM Healthcare Investments, which will support a Phase II trial of its leading cancer vaccines in combination with...

In the wake of the storming of the U.S. Capitol, BIO and PhRMA have joined other trade associations and U.S. companies in reassessing their criteria for making political contributions. The biopharma trade associations have not...

More than a decade after Kymab was first backed by the Wellcome Trust to derive drug candidates from an engineered mouse model, the company has accepted a $1.1 billion takeout offer from Sanofi that closely...

First they came for the climate scientists, and I did not speak out because I wasn’t a climate scientist. Then they came for the mask-wearers, and I did not speak out because I was...

After a quiet first nine months, Paris-based VC Jeito ended 2020 with a trio of investments and a €50 million infusion by Sanofi. And while all three venture plays were in early-stage gene and cell...

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...

The reckoning that will come after the pandemic will see broad if not tectonic shifts in drug development, from clinical trial conduct to scientific publishing, according to bioethicist Arthur Caplan....